Patient Experiences of Multiple Sclerosis (PExMS)
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jan 20, 2020
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Patient Experiences of Multiple Sclerosis (PExMS) trial is studying how a special website can help people with relapsing-remitting multiple sclerosis (MS) make better decisions about their treatment options, specifically immunotherapies. This website will provide not only factual information about these treatments but also share real-life experiences from other patients. The hope is that these personal stories will make it easier for individuals to decide whether to start, switch, or stop their current treatment.
To participate in this trial, you must be at least 18 years old, have been diagnosed with relapsing-remitting MS, and be considering a change in your immunotherapy. Unfortunately, if you have another form of MS or significant cognitive challenges, you won't be eligible. The trial is not yet recruiting participants, but if you join, you can expect to explore the website and provide feedback on how it helped you in your decision-making process. Your input could play an important role in improving resources for others living with MS.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • persons with relapsing-remitting multiple sclerosis
- • being ≥18 years old
- • considering starting, switching or stopping any immunotherapy
- Exclusion Criteria:
- • persons with secondary progressive multiple sclerosis or primary progressive multiple sclerosis
- • persons with major cognitive deficits
- • persons having poor German language skills
- • persons who participated in the development phase of the PExMS-website, which took place prior to the pilot randomised controlled trial
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Christoph Heesen, Prof. Dr.
Principal Investigator
Universitätsklinikum Hamburg-Eppendorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials